Gilead press­es for­ward with next-gen CAR-T, ink­ing deal with small syn­thet­ic bi­ol­o­gy start­up

Gilead is dip­ping its toes in­to some ear­ly-stage dis­cov­ery work.

Through its sub­sidiary Kite Phar­ma, Gilead signed a deal with Cal­i­for­nia biotech Refuge Biotech­nolo­gies to ac­cess a gene ex­pres­sion plat­form with the goal of de­vel­op­ing cell ther­a­pies for blood can­cers. No dol­lar amounts were dis­closed, but Gilead said in a press re­lease that the deal fits in its larg­er mis­sion to cre­ate a “new gen­er­a­tion” of CAR-Ts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER